Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Real World Superiority Data May Not Be Enough To Boost GSK's Breo In COPD

Executive Summary

Breo Ellipta is associated with a lower rate of exacerbations in real world Salford study, but some analysts question whether it's too late to turn performance around in a highly competitive, highly price-conscious market.


Related Content

GSK Leads Way With Real World Data, But Others Follow
GSK’s Breo Fails To Reach Peak In SUMMIT Survival Study
“Real-World” Breo Study: A Q&A With GSK’s David Leather


Related Companies